利拉鲁肽联合短期胰岛素强化治疗初诊肥胖2型糖尿病患者的效果及对其血清指标学的影响

Effect of liraglutide combined with short-term intensive insulin therapy in newly diagnosed obese patients with diabetes mellitus type 2 and its serum indexes evaluation

下载PDF

导出

摘要目的分析利拉鲁肽联合短期胰岛素强化治疗初诊肥胖2型糖尿病(T2DM)患者的效果及对血清指标学的影响。方法选取2019年10月至2020年9月本院收治的120例初诊肥胖T2DM患者作为研究对象,采用双盲法抽签分为对照组和观察组,每组60例。对照组采用短期胰岛素治疗,观察组在对照组基础上联合利拉鲁肽治疗,比较两组治疗前后血糖指标[空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbAlc)],肥胖相关指标[体重指数(BMI)、腰围、内脏脂肪面积],血清学指标[趋化素(CHEM)、内脂素、丙二醇(MDA)、谷胱甘肽过氧化物酶(GSH-Px)]变化及不良反应发生情况。结果治疗前,两组FBG、2 h PBG、HbAlc水平比较差异均无统计学意义;治疗后,两组FBG、2 hPBG、HbAlc水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组BMI、腰围、内脏脂肪面积比较差异均无统计学意义;治疗后,两组BMI均低于治疗前,腰围、内脏脂肪面积均小于治疗前,且观察组BMI低于对照组,腰围、内脏脂肪面积均小于对照组,差异有统计学意义(P<0.05)。治疗前,两组CHEM、内脂素、MDA、GSH-PX水平比较均差异无统计学意义;治疗后,两组CHEM、内脂素、MDA水平均低于治疗前,GSH-PX水平高于治疗前,且观察组CHEM、内脂素、MDA水平均低于对照组,GSH-PX水平高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论采用利拉鲁肽联合短期胰岛素治疗初诊肥胖T2DM患者,可有效降低血糖指标水平及体质量,改善血清学指标,促进糖脂代谢,促进疾病转归效果显著。 Objective To analyze the efficacy and serum index effect of liraglutide combined with short-term intensive insulin therapy in patients with newly diagnosed obese type 2 diabetes mellitus(T2DM).Methods Atotal of 120 patients with newly diagnosed obesity T2DMadmitted to our hospital from October 2019 to September 2020 were selected as the research subjects,and they were divided into control group and observation group according to double-blind method,with 60 cases in each group.The control group was treated with short-term insulin,and the observation group was treated with liraglutide on the basis of the control group,and the blood glucose indexes before and after treatment(fasting blood glucose[FBG],2 h postprandial blood glucose[2 h PBG],glycosylated hemoglobin-typeA1c[HbAlc]),obesity-related indicators(body mass index[BMI],waist circumference,visceral fat area)level,serum index(chemerin[CHEM],visfatin,propylene glycol[MDA],Glutathione peroxidase[GSH-Px])changes,occurrence of adverse reactions were compared between two groups.Results Before treatment,there were no significant differences in FBG,2 hPBG and HbAlc levels between the two groups;after treatment,the levels of FBG,2 hPBG and HbAlc in the two groups were lower than before treatment,and the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in BMI,waist circumference and visceral fat area between the two groups;after treatment,the BMI of two groups were lower than those before treatment,the waist circumference and visceral fat area of two groups were smaller than those before treatment,and the BMI of the observation group was lower than that of the control group,and the waist circumference and visceral fat area were smaller than those of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of CHEM,endolipids,MDA,and GSH-PX between the two groups;af

作者赵文月李淑文刘月晅 ZHAO Wenyue;LI Shuwen;LIU Yuexuan(Department of Endocrine,Dandong Central Hospital,Dandong,Liaoning,118000,China)

机构地区丹东市中心医院内分泌科

出处《当代医学》 2022年第32期20-24,共5页 Contemporary Medicine

关键词 T2DM 初诊肥胖患者利拉鲁肽短期胰岛素血糖血清指标学 Diabetes mellitus type 2 Newly diagnosed obese patients Liraglutide Short-term insulin Blood sugar Serological indicators

分类号 R58 [医药卫生—内分泌]